This can be assessed through liver biopsies or noninvasive methods, such as FibroScan, measurement of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in the blood, and the calculation of fibrosis indices (e.g., NAFLD Fibrosis Score or Fibrosis-4 Index). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.